Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 17/20 | 0.59 |
| ▸ | AOC2 | O75106 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | DAO | P14920 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23701754 | 0.81 | AOC3 (0.61) | AOC3AOC2MAOAMAOBDAO | |
| SCHEMBL23701753 | 0.81 | AOC3 (0.61) | AOC3AOC2MAOAMAOBDAO | |
| SCHEMBL23718609 | 0.78 | AOC3 (0.64) | AOC3AOC2MAOAMAOBDAO | |
| Hydrochloric Acid SCHEMBL23701841 | 0.77 | AOC3 (0.62) | AOC3AOC2MAOAMAOBDAO | |
| SCHEMBL20714309 | 0.75 | AOC3 (0.64) | AOC3AOC2MAOAMAOBDAO | |
| SCHEMBL20714060 | 0.75 | AOC3 (0.64) | AOC3AOC2MAOAMAOBDAO | |
| SCHEMBL23718739 | 0.75 | AOC2 (0.81) | AOC3AOC2MAOAMAOBDAO | |
| SCHEMBL23718741 | 0.75 | AOC2 (0.81) | AOC3AOC2MAOAMAOBDAO | |
| Hydrochloric Acid SCHEMBL29037068 | 0.74 | AOC3 (0.62) | AOC3AOC2MAOAMAOBDAO | |
| Hydrochloric Acid SCHEMBL29037073 | 0.74 | AOC3 (0.62) | AOC3AOC2MAOAMAOBDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238192-A1 | VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238192-A1 | VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238192-A1 | VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF | VCAM1, VAPB, ICAM1 | AOC3 796/4885AOC2 807/4885MAOA 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.